Appointment of Dr. Bryan Jones as an Advisor to Lead Sol-Gel Special Projects
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) has appointed Dr. Bryan Jones as Director of Sol-Gel Special Projects, effective January 31, 2025. Dr. Jones brings over 30 years of drug development experience and currently serves as Chief Operating Officer of Aardvark Therapeutics. His extensive background includes co-founding Sollis Therapeutics and Sherrington Pharmaceuticals, with experience at Bristol-Myers Squibb and work on products like Cialis.
Dr. Jones holds a Ph.D. in Genetics from the University of Washington and will focus on advancing PreveCeutical's Sol-Gel program for Nose to Brain delivery of therapeutics. The company aims to develop preventive and curative therapies using organic and nature identical products. CEO Stephen Van Deventer expressed that Dr. Jones's expertise will help accelerate the program, with details on their first targeted therapeutic forthcoming.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) ha nominato Dr. Bryan Jones come Direttore dei Progetti Speciali Sol-Gel, con decorrenza dal 31 gennaio 2025. Il Dr. Jones porta con sé oltre 30 anni di esperienza nello sviluppo di farmaci e attualmente ricopre il ruolo di Chief Operating Officer presso Aardvark Therapeutics. Il suo ampio background include la co-fondazione di Sollis Therapeutics e Sherrington Pharmaceuticals, con esperienze presso Bristol-Myers Squibb e lavori su prodotti come Cialis.
Il Dr. Jones è in possesso di un Ph.D. in Genetica presso l'Università di Washington e si concentrerà sull'avanzamento del programma Sol-Gel di PreveCeutical per la somministrazione di terapie dal naso al cervello. L'azienda mira a sviluppare terapie preventive e curative utilizzando prodotti organici e identici alla natura. Il CEO Stephen Van Deventer ha dichiarato che l'expertise del Dr. Jones aiuterà ad accelerare il programma, con dettagli sulla loro prima terapia mirata in arrivo.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) ha nombrado al Dr. Bryan Jones como Director de Proyectos Especiales Sol-Gel, con efecto a partir del 31 de enero de 2025. El Dr. Jones aporta más de 30 años de experiencia en el desarrollo de medicamentos y actualmente se desempeña como Director de Operaciones en Aardvark Therapeutics. Su amplia experiencia incluye la co-fundación de Sollis Therapeutics y Sherrington Pharmaceuticals, así como experiencia en Bristol-Myers Squibb y en productos como Cialis.
El Dr. Jones tiene un Ph.D. en Genética de la Universidad de Washington y se centrará en avanzar en el programa Sol-Gel de PreveCeutical para la entrega terapéutica de nariz a cerebro. La empresa tiene como objetivo desarrollar terapias preventivas y curativas utilizando productos orgánicos e idénticos a los de la naturaleza. El CEO Stephen Van Deventer expresó que la experiencia del Dr. Jones ayudará a acelerar el programa, con detalles sobre su primera terapia dirigida que se anunciarán pronto.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF)는 Bryan Jones 박사를 특수 프로젝트 솔-겔 담당 이사로 임명했습니다. 임기는 2025년 1월 31일부터 시작됩니다. Jones 박사는 30년 이상의 의약품 개발 경험을 가지고 있으며 현재 Aardvark Therapeutics의 COO로 재직 중입니다. 그의 광범위한 경력에는 Sollis Therapeutics 및 Sherrington Pharmaceuticals의 공동 설립이 포함되며, Bristol-Myers Squibb에서의 경험과 Cialis와 같은 제품 작업을 포함합니다.
Jones 박사는 워싱턴 대학교에서 유전학 박사 학위를 보유하고 있으며, PreveCeutical의 솔-겔 프로그램을 코에서 뇌로 약물을 전달하는 데 초점을 맞출 것입니다. 이 회사는 유기적이며 자연과 동일한 제품을 사용하여 예방 및 치료법을 개발하는 것을 목표로 합니다. CEO Stephen Van Deventer는 Jones 박사의 전문성이 프로그램을 가속화하는 데 도움이 될 것이라고 표현했으며, 첫 번째 목표 치료제에 대한 자세한 내용은 곧 발표될 예정입니다.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) a nommé Dr. Bryan Jones au poste de Directeur des Projets Spéciaux Sol-Gel, effectif à partir du 31 janvier 2025. Le Dr Jones apporte plus de 30 ans d'expérience dans le développement de médicaments et occupe actuellement le poste de Directeur des Opérations chez Aardvark Therapeutics. Son vaste parcours inclut la co-fondation de Sollis Therapeutics et de Sherrington Pharmaceuticals, ainsi qu'une expérience chez Bristol-Myers Squibb et des travaux sur des produits comme Cialis.
Le Dr Jones détient un Ph.D. en Génétique de l'Université de Washington et se concentrera sur l'avancement du programme Sol-Gel de PreveCeutical pour la délivrance thérapeutique du nez au cerveau. L'entreprise vise à développer des thérapies préventives et curatives en utilisant des produits organiques et identiques à la nature. Le PDG Stephen Van Deventer a exprimé que l'expertise du Dr Jones aidera à accélérer le programme, avec des détails sur leur première thérapie ciblée à venir.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) hat Dr. Bryan Jones zum Direktor für Sonderprojekte im Bereich Sol-Gel ernannt, mit Wirkung zum 31. Januar 2025. Dr. Jones bringt über 30 Jahre Erfahrung in der Arzneimittelentwicklung mit und ist derzeit Chief Operating Officer von Aardvark Therapeutics. Sein umfangreicher Hintergrund umfasst die Mitbegründung von Sollis Therapeutics und Sherrington Pharmaceuticals sowie Erfahrungen bei Bristol-Myers Squibb und Arbeiten an Produkten wie Cialis.
Dr. Jones hat einen Ph.D. in Genetik von der University of Washington und wird sich auf die Weiterentwicklung von PreveCeuticals Sol-Gel-Programm zur Abgabe von Therapeutika von der Nase zum Gehirn konzentrieren. Das Unternehmen hat sich zum Ziel gesetzt, präventive und heilende Therapien mit organischen und natürlichen Produkten zu entwickeln. CEO Stephen Van Deventer äußerte, dass die Expertise von Dr. Jones dazu beitragen wird, das Programm zu beschleunigen, wobei nähere Informationen zu ihrer ersten gezielten Therapie bald veröffentlicht werden.
- Appointment of experienced pharmaceutical executive with 30+ years in drug development
- Strategic expertise in both scientific and business development aspects
- Track record of successful exits (Sherrington Pharmaceuticals sold to Sorrento Therapeutics)
- Experience in leading Phase 3 clinical trials and drug manufacturing
- None.
Vancouver, British Columbia--(Newsfile Corp. - February 4, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), (the "Company" or "PreveCeutical") a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products is pleased to announce that is has appointed Dr. Bryan Jones ("Bryan") as an advisor to the Company as Director of Sol-Gel Special Projects effective 31 January, 2025.
Bryan Jones brings over 30 years of drug development experience from both a scientific and business development aspect. He is currently the Chief Operating Officer of Aardvark Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.
Prior to joining Aardvark, he was Co-Founder of Sollis Therapeutics Inc. and served as its Chief Operating Officer from May 2017 to May 2020, where he led technology transfer, manufacturing of a drug/device combination, and execution of the company's Phase 3 Sciatica program. He was also a Co-founder of Sherrington Pharmaceuticals which was sold to Sorrento Therapeutics in 2013.
He started his career in the laboratory at Bristol-Myers Squibb Company and on products such as Cialis® with ICOS and has held progressively higher positions in Business Development, Operations and C-Suite roles during the course of his career.
Dr. Jones received his Ph.D. in Genetics from the University of Washington and a bachelor's degree in biology and Biochemistry from Iowa State University.
Stephen Van Deventer, CEO of PreveCeutical, commented:
"Having Bryan join our team to advance Sol-Gel to deliver Nose to Brain delivery of different therapeutics to prevent or manage symptoms caused by disease and other ailments, will allow us to accelerate this program rapidly. In the near term we will provide further details on our first targeted therapeutic. Bryan's expertise and experience will be a great asset to PreveCeutical."
Bryan Jones remarked on his appointment:
"The science developed at PreveCeutical has the potential to increase the therapeutic window and result in much safer treatment options for patients. I am excited to work with the team to advance this innovative technology into as many different therapeutic options as feasible."
About PreveCeutical
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.
On behalf of the Board of Directors of PreveCeutical
Stephen Van Deventer, Chairman and Chief Executive Officer
For further information, please contact:
Stephen Van Deventer: +1 604 306 9669
Or Investor Relations ir@preveceutical.com
Forward-Looking Statements:
This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future, including, without limitation, the continued research interests of PreveCeutical, PreveCeutical's anticipated business plans, and its prospects of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as "will", "pro forma", "plans", "expects", "may", "should", "budget", "schedules", "estimates", "forecasts", "intends", "anticipates", "believes", "potential", "proposes" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding PreveCeutical, including expected growth, results of operations, including PreveCeutical's research and development activities, performance, industry trends, growth opportunities, that PreveCeutical will be granted requisite expedited approvals by world health, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights needed to carry out future business activities.
Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to: complexities and delays in connection with research and development activities and the actual results of research and development activities; the ability of PreveCeutical to, among other things, protect its respective intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities and obtaining expedited requisite approvals from world health agencies; and the ability of PreveCeutical to commercialize products, pursue business partnerships, complete their research programs as planned, and obtain the financing required to carry out their planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry may also adversely affect the future results or performance of PreveCeutical. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, PreveCeutical assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although PreveCeutical believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by PreveCeutical from time-to-time. These reports and PreveCeutical's filings are available at www.sedar.com. Neither the Canadian Securities Exchange (CSE or CNSX Markets), its Regulation Services Provider (as that term is defined in policies of the CSE), nor any other regulatory authority accepts responsibility for the adequacy or accuracy of this release.
Any link in this press release to external information or other resources is provided for reference only, and such information or resources might change from time to time, and may include forward-looking statements as described above, and are subject to the above disclaimers under this heading forward-looking statements.
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/239524
FAQ
What is Dr. Bryan Jones's role at PreveCeutical Medical (PRVCF)?
What is PreveCeutical's (PRVCF) Sol-Gel program focusing on?
What is Dr. Bryan Jones's background before joining PRVCF?
When will PRVCF announce details about their first targeted therapeutic?
